Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 10/20 | 0.53 |
| ▸ | PRKCA | P17252 | 5/20 | 0.53 |
| ▸ | PRKCD | Q05655 | 4/20 | 0.53 |
| ▸ | EGFR | P00533 | 2/20 | 0.53 |
| ▸ | BCR | P11274 | 8/20 | 0.50 |
| ▸ | CDK2 | P24941 | 7/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.45 |
| ▸ | PRKCG | P05129 | 1/20 | 0.45 |
| ▸ | PRKCB | P05771 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | PRKCH | P24723 | 1/20 | 0.45 |
| ▸ | PRKCI | P41743 | 1/20 | 0.45 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.45 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.45 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.45 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.45 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13683318 | 0.84 | ABL1 (0.72) | ABL1PRKCAPRKCDEGFRBCR | |
| SCHEMBL8246547 | 0.84 | ABL1 (0.58) | ABL1PRKCAPRKCDEGFRBCR | |
| SCHEMBL12837140 | 0.80 | ABL1 (0.58) | ABL1PRKCAPRKCDEGFRBCR | |
| SCHEMBL8246544 | 0.80 | ABL1 (0.58) | ABL1PRKCAPRKCDEGFRBCR | |
| SCHEMBL8253620 | 0.80 | PRKCA (0.55) | ABL1PRKCAPRKCDEGFRBCR | |
| SCHEMBL11924749 | 0.79 | ABL1 (0.62) | ABL1PRKCAPRKCDEGFRBCR | |
| SCHEMBL8255847 | 0.78 | PIK3CG (0.59) | ABL1PRKCAPRKCDEGFRBCR | |
| SCHEMBL8252396 | 0.77 | ABL1 (0.77) | ABL1PRKCAPRKCDEGFRBCR | |
| SCHEMBL805400 | 0.74 | ABL1 (0.73) | ABL1PRKCAEGFRBCRPDGFRB | |
| SCHEMBL6262145 | 0.71 | ABL1 (1.00) | ABL1PRKCAPRKCDEGFRBCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120208846-A1 | Therapeutic Methods For Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2012-08-16 | — | — | US | disclosed |
| US-7897572-B1 | Theraputic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) | 2011-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208846-A1 | Therapeutic Methods For Type I Diabetes | MAPK9, IAPP, RNASE1 | ABL1 1532/4885PRKCA 159/4885PRKCD 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.